A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
PHASE2CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
July 31, 1997
Study Completion Date
April 30, 2000
Conditions
Multiple Sclerosis
Interventions
DRUG
rhIGF-1 (CEP-151)
Trial Locations (1)
20892
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda
All Listed Sponsors
lead
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
NCT00001669 - A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients | Biotech Hunter | Biotech Hunter